Epitopea, a transatlantic cancer immunotherapeutics company and global specialist in exploiting a new class of untapped tumour-specific antigens (TSAs), has secured a $13.6 million (£10.3 million) seed investment from a transatlantic syndicate of top-tier life sciences investors, including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ.
The seed round was also supported by Novateur Ventures and the Harrington Discovery Institute/University Health Holdings.
The funding will leverage Epitopea’s Cryptigen approach to create transformational immunotherapies that target broad cancer patient populations in both solid and haematological cancers.
The seed round funding will be used to build the company’s executive team, advance further research on this new class of antigens, and catalyse their translation into novel cancer immunotherapeutics, including therapeutic vaccines, cell therapies, and TCR-based biologics.
